NVSEF News and Press, Novartis Ag Basel Akt From 11/19/23

2023-11-19 02:00:00 ET Summary Legend Biotech partners with Novartis in a $1.2 billion deal to develop and commercialize DLL3 CAR-T candidates. WuXi XDC, an ADC/bioconjugate CRDMO, raises $520 million in a successful IPO in Hong Kong. Shanghai SciClone Pharma acquires China ri...

2023-11-16 23:16:56 ET Summary Vertex Pharmaceuticals Incorporated is a global $90-billion market-cap biotechnology company specializing in developing transformative medicines. Despite the close-to-zero growth in EPS, the Company maintained a strong financial position, ending the ...

2023-11-13 15:24:10 ET Novartis AG (NVS) 10th Annual ESG Investor Event Conference November 13, 2023 10:30 AM ET Company Participants Maria Victoria Cuevas - IR Vas Narasimhan - CEO Lutz Hegemann - President, Global Health & Sustainability Thierry Diagana...

2023-11-10 12:14:28 ET More on Celldex Celldex: Mast Cell Disease Targeting Continues To Make Advancements In Clinic Celldex Therapeutics announces pricing of public offering of common stock Celldex Therapeutics announces proposed public offering of common stock ...

2023-11-06 17:56:31 ET Summary iShares MSCI EAFE ETF provides exposure to large and mid-sized companies across developed markets outside the U.S. and Canada. EFA has a diverse portfolio with holdings in sectors such as financials, healthcare, industrials, consumer discretionary, a...

2023-10-30 15:11:22 ET More on Novartis, Novartis AG, etc. New And Improved Novartis Novartis AG (NVS) Q3 2023 Earnings Call Transcript Novartis AG (NVS) Shareholder Analyst Call (Transcript) Novartis reports Q3 earnings boosted by strong sales of key drugs a...

2023-10-29 12:00:27 ET More on PBMs Cigna PBM unit Express Scripts sued for overcharging pharmacies FTC investigating purchasing organizations that work on behalf of PBMs Eli Lilly, Novo, Sanofi and leading PBMs accused in California over insulin prices CVS H...

2023-10-27 07:35:00 ET Summary Investors are worried about soaring interest rates, a pending government shutdown, wars around the world, and a recession looming next year. History is very clear, market timing is the WORST thing you can possibly try. None of the best investors in h...

2023-10-24 13:55:26 ET Novartis AG (NVS) Q3 2023 Earnings Call Transcript October 24, 2023, 08:00 AM ET Company Participants Samir Shah - Global Head of Investor Relations Vas Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Confe...

2023-10-24 11:23:00 ET Summary Ambrx Biopharma Inc. common stock experienced an irrational selloff following the Phase 1/2 ESMO data release for its ADC candidate ARX517, presenting a buying opportunity. The company's technology for next-generation ADCs has shown safety benefits a...